Strategic white matter tracts for processing speed deficits in age-related small vessel disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 30, 2013
- Accepted in final form January 21, 2014
- First Published May 2, 2014.
Article Versions
- Previous version (May 2, 2014 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Marco Duering, MD*,
- Benno Gesierich, PhD*,
- Stephan Seiler, MD,
- Lukas Pirpamer,
- Mariya Gonik, PhD,
- Edith Hofer, PhD,
- Eric Jouvent, MD, PhD,
- Edouard Duchesnay, PhD,
- Hugues Chabriat, MD, PhD,
- Stefan Ropele, PhD,
- Reinhold Schmidt, MD and
- Martin Dichgans, MD
- Marco Duering, MD*,
NONE
NONE
travel expenses for lectures from the United Leukodystrophy Foundation, the European Stroke Conference and Kenes International
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Vascular Dementia Research Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Benno Gesierich, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stephan Seiler, MD,
NONE
NONE
(1) Lundbeck, travel funding
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Rotary Club Innsbruck
NONE
NONE
NONE
NONE
NONE
NONE
- Lukas Pirpamer,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
as reported in the manuscript: This work was supported by the Vascular Dementia Research Foundation, the German Center for Neurodegenerative iseases (DZNE), an FP6 ERA-NET NEURON grant (01 EW1207),3 Fondation Leducq (Transatlantic Network of Excellence on he Pathogenesis of Small Vessel Disease of the Brain) and by the Austrian Science Fund projects P20103 and I904.
NONE
NONE
NONE
NONE
NONE
NONE
- Mariya Gonik, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Edith Hofer, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Jouvent, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Edouard Duchesnay, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hugues Chabriat, MD, PhD,
Lundbeck, Janssen
NONE
NONE
Cerebrovascular disease (member of the editorial board)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Ropele, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Reinhold Schmidt, MD and
Rivastigmin Patch, 2010, Novartis JSW Life Sciences 2010, Advisory Board for Dementia Trial Axon Neuroscience 2013
NONE
Received travel expenses and/or honoraria for lectures from Pfizer (2004-2010), Novartis (2003-2010), Merz Austria (2005-2010) and Lundbeck (2004-2009) and for educational activity from Takeda 2010
Editoral board member of Clinical Neurology and Neurosurgery 2004-currently
NONE
NONE
Pfizer 2004-2010,lectures Novartis 2003-2010, lectures Merz Austria 2005-2010, lectures Lundbeck 2004-2009, lectures Takeda, 2010, teaching course
QPS, Austria Axon Neuroscience
NONE
NONE
NONE
NONE
Austrian Science Fund projects P20103 and I904
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Dichgans, MD
NONE
NONE
(1) Bayer Vital, travel expenses and honoraria for lectures, (2) Boehringer Ingelheim Pharma, travel expenses and honoraria for lectures, (3) Heel, travel expenses and honoraria for lectures, (4) Bristol-Meyer Squibb, travel expenses and honoraria for lectures, (5) Lundeck, travel expenses and honoraria for lectures, (6) Sanofi-Aventis, travel expenses and honoraria for lectures, (7) Shire, travel expenses and honoraria for lectures, (8) German Research Foundation (DFG), research support, (9) Vascular Dementia Research Foundation, research support, (10) Corona Foundation, research support, (11) Jackst�dt Foundation, research support.
(1) Stroke the International Journal of Stroke, editor, (2) Cerebrovascular diseases, editorial board member, (3) Journal of Neurochemistry, editor
NONE
NONE
NONE
(1) Bayer Vital, (2) Boehringer Ingelheim, (3) Bristol-Meyer Squibb, (4) Heel
NONE
NONE
NONE
NONE
(1) Wellcometrust, 03/08 following, (2) European Union (EU FP 7), investigator, 10/13-09/16, (3) German Federal Ministry of Education and Research (BMBF), investigator, 12/13-11/16, (4) European Union (EU FP 6), investigator, 03/12-02/15
NONE
(1) Vascular Dementia Research Foundation, (2) Corona Foundation, (3) Jackst�dt Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute for Stroke and Dementia Research (M. Duering, B.G., M.G., M. Dichgans), Klinikum der Universität München, Munich, Germany; the Department of Neurology (S.S., L.P., E.H., S.R., R.S.), Medical University of Graz; the Institute for Medical Informatics, Statistics and Documentation (E.H.), Graz, Austria; the Department of Neurology (E.J., H.C.), CHU Lariboisière, Assistance Publique des Hôpitaux de Paris; Neurospin (E.D.), CEA Saclay, Gif sur Yvette, France; the German Center for Neurodegenerative Diseases (DZNE, Munich) (M. Dichgans); and Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans), Munich, Germany.
- Correspondence to Dr. Dichgans: martin.dichgans{at}med.uni-muenchen.de
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.